bullish
Opthea Ltd (OPT AU): Secured Funds as Lead Eye Drug Candidate Advancing in Phase 3 Trials
324 Views28 Nov 2022 10:58
SUMMARY
- Opthea Ltd (OPT AU) secured up to $170M in non-dilutive financing from Launch Therapeutics, which is backed by Carlyle Group Inc (CG US) and its life sciences franchise, Abingworth.
- Opthea has closed $90 million equity financing placement at a price of A$1.15 per share in two tranches. Further, the company has raised A$5 million through right issue.
- These strategic transactions are expected to fund Opthea through Phase 3 topline data expected in mid-2024 and strengthens its strategic position to maximize the value of OPT-302.
Related Insights
More »- Opthea Limited - Blindsided: COAST Phase III Flop
- Opthea Limited - Offshore Result: Implications from REGN 4Q24 Update
- Opthea Limited - Eye on the Prize: Zooming in on OPT-302
- Opthea (OPT AU): Getting Closer to Commercialization of First Drug; Fund Raising Adds to Confidence
- Opthea (OPT AU): Kicks Off A$80M Capital Raise To Support Phase 3 Trial of Lead Drug Candidate
Trending Collections
More »Trending Insights
More »- Yageo Bigly Overbids Minebea (+20%) For Shibaura Elec (6957) At ¥5400
- Shibaura Electronics (6957 JP): No Messing Around as Yageo (2327 TT) Returns with a JPY5,400 Offer
- Shein: London Approves IPO but Tariffs and End Of "De Minimis" Exemption to Lower Valuation
- De Grey Mining/Northern Star Resources: The Passive Flows
- Smartkarma Webinar | ASEAN Markets Outlook: Drivers, Policies & Risks in 2025
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Opthea (OPT AU): Getting Closer to Commercialization of First Drug; Fund Raising Adds to Confidence03 Sep 2024
- Opthea (OPT AU): Kicks Off A$80M Capital Raise To Support Phase 3 Trial of Lead Drug Candidate25 Aug 2023
- Opthea Ltd (OPT AU): Secured Funds as Lead Eye Drug Candidate Advancing in Phase 3 Trials28 Nov 2022
- Opthea Ltd (OPT AU): Lead Asset for Highly Prevalent Retinal Disease Moving Toward Commercialization04 Aug 2022
x